Which of the following medications is considered an anabolic agent for treating osteoporosis?

Abaloparatide is recognized as an anabolic agent for the treatment of osteoporosis. Anabolic agents work by stimulating bone formation, which is particularly important in patients with osteoporosis who require enhancement of bone density. Abaloparatide is a synthetic analog of parathyroid hormone and acts on bone tissue to promote new bone growth and improve bone mineral density, therefore reducing the risk of fractures.

In contrast, the other medications listed primarily function by inhibiting bone resorption rather than actively stimulating bone formation. Ibandronate and Alendronate are bisphosphonates that reduce bone breakdown, while Raloxifene is a selective estrogen receptor modulator (SERM) that provides estrogen-like effects on bone but does not stimulate bone formation in the same way that anabolic agents do. This distinction is critical in understanding how different medications are utilized in the management of osteoporosis and their mechanisms of action.